These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 39402091)

  • 1. Effectiveness and safety of azvudine versus nirmatrelvir-ritonavir in adult patients infected with COVID-19 omicron strains: a retrospective study in Beijing.
    Xie H; Wang Y; Xu Y; Wang L; Fan J; Pan S; Shi C; Liu X; Gao X; Guo X; Yu S; Liu J; Zhang D; Yang Y; Zhang H; Wang J; Wu A; Liu X; Liu J; Zhu H; Zhou X; Tian X; Wang M
    Sci Rep; 2024 Oct; 14(1):23974. PubMed ID: 39402091
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Real-world effectiveness of nirmatrelvir-ritonavir versus azvudine in hospitalized patients with COVID-19 during the omicron wave in Beijing: a multicenter retrospective cohort study.
    Han X; Gao D; Li C; Yuan X; Cui J; Zhao W; Xie F; Wang K; Liu Y; Muo G; Xi N; Zheng M; Wang R; Xiao K; Zhao D; Zhang X; Han X; Wang B; Zhang T; Xie W; Xie L
    BMC Infect Dis; 2024 Jan; 24(1):57. PubMed ID: 38191304
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of azvudine, molnupiravir, and nirmatrelvir/ritonavir in adult patients with mild-to-moderate COVID-19: a retrospective cohort study.
    Chen MP; Jiang DX; Rang JX; Zhuo HB; Zhou ZG
    Sci Rep; 2024 Feb; 14(1):3318. PubMed ID: 38337014
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effectiveness of nirmatrelvir-ritonavir versus azvudine for adult inpatients with severe or critical COVID-19.
    Zhang H; Xiaojiao T; Chen J; Zhang Z; Wang C; Shi H; Li Y; Li J; Kang Y; Jin X; Liao X
    BMJ Open Respir Res; 2024 Apr; 11(1):. PubMed ID: 38599779
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effectiveness of the antiviral medications azvudine and nirmatrelvir-ritonavir in treating COVID-19 in patients with hematological malignancies.
    Zeng Z; Li F; Zhong M; Zhu L; Chen W; Wang X
    Clinics (Sao Paulo); 2024; 79():100406. PubMed ID: 39059144
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Real-world effectiveness of Azvudine versus nirmatrelvir-ritonavir in hospitalized patients with COVID-19: A retrospective cohort study.
    Deng G; Li D; Sun Y; Jin L; Zhou Q; Xiao C; Wu Q; Sun H; Dian Y; Zeng F; Pan P; Shen M
    J Med Virol; 2023 Apr; 95(4):e28756. PubMed ID: 37185838
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Azvudine versus Paxlovid in COVID-19: A systematic review and meta-analysis.
    Amani B; Amani B
    Rev Med Virol; 2024 Jul; 34(4):e2551. PubMed ID: 38849982
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Azvudine and nirmatrelvir-ritonavir in hospitalized patients with moderate-to-severe COVID-19: Emulation of a randomized target trial.
    Zhou Y; Liu Y; Jiang L; Zhang R; Zhang H; Shi Q; Yang Z; Mao Y; Liu S; Yang Z; Ding J; Zhou Y; Ren B; He L; Zhao X; Li W; Li S; Liu D
    J Med Virol; 2023 Dec; 95(12):e29318. PubMed ID: 38112106
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antiviral Effectiveness, Clinical Outcomes, and Artificial Intelligence Imaging Analysis for Hospitalized COVID-19 Patients Receiving Antivirals.
    Gao Y; Dong Y; Bu Q; Gong Z; Wang W; Zhou Z; Gao Y; Liu L; Wu M; Zhang J; Liang L; Li H; Jiang M; Luo Z; Ma Y; Zhang X; Hu Z
    Influenza Other Respir Viruses; 2024 Sep; 18(9):e70006. PubMed ID: 39284764
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effectiveness and safety of azvudine in older adults with mild and moderate COVID-19: a retrospective observational study.
    Zhou Z; Zheng H; Xiao G; Xie X; Rang J; Peng D
    BMC Infect Dis; 2024 Jan; 24(1):47. PubMed ID: 38177982
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antiviral effectiveness and survival correlation of azvudine and nirmatrelvir/ritonavir in elderly severe patients with COVID-19: a retrospective real-world study.
    Wang S; Sun J; Zhang X; Li M; Qin B; Liu M; Zhang N; Wang S; Zhou T; Zhang W; Ma C; Deng X; Bai Y; Qu G; Liu L; Shi H; Zhou B; Li K; Yang B; Li S; Wang F; Ma J; Zhang L; Wang Y; An L; Liu W; Chang Q; Zhang R; Yin X; Yang Y; Ao Q; Ma Q; Yan S; Huang H; Song P; Gao L; Lu W; Xu L; Lei L; Wang K; Zhang Q; Song Q; Zhang Z; Fang X; He Y; Li T; Zhu P
    EClinicalMedicine; 2024 Mar; 69():102468. PubMed ID: 38361990
    [TBL] [Abstract][Full Text] [Related]  

  • 12. VV116 versus Nirmatrelvir-Ritonavir for Oral Treatment of Covid-19.
    Cao Z; Gao W; Bao H; Feng H; Mei S; Chen P; Gao Y; Cui Z; Zhang Q; Meng X; Gui H; Wang W; Jiang Y; Song Z; Shi Y; Sun J; Zhang Y; Xie Q; Xu Y; Ning G; Gao Y; Zhao R
    N Engl J Med; 2023 Feb; 388(5):406-417. PubMed ID: 36577095
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Real-world use of nirmatrelvir-ritonavir in outpatients with COVID-19 during the era of omicron variants including BA.4 and BA.5 in Colorado, USA: a retrospective cohort study.
    Aggarwal NR; Molina KC; Beaty LE; Bennett TD; Carlson NE; Mayer DA; Peers JL; Russell S; Wynia MK; Ginde AA
    Lancet Infect Dis; 2023 Jun; 23(6):696-705. PubMed ID: 36780912
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effectiveness and safety of Sanhan Huashi granules versus nirmatrelvir-ritonavir in adult patients with COVID-19: A randomized, open-label, multicenter trial.
    Zou X; Chang K; Fan G; Zheng H; Shen H; Tang L; Yang Y; Wang Y; Zhao L; Lv H; Zhou X; Shen X; Chen L; Tong X; Cao B;
    Sci Bull (Beijing); 2024 Jun; 69(12):1954-1963. PubMed ID: 38749859
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Real-world effectiveness of early molnupiravir or nirmatrelvir-ritonavir in hospitalised patients with COVID-19 without supplemental oxygen requirement on admission during Hong Kong's omicron BA.2 wave: a retrospective cohort study.
    Wong CKH; Au ICH; Lau KTK; Lau EHY; Cowling BJ; Leung GM
    Lancet Infect Dis; 2022 Dec; 22(12):1681-1693. PubMed ID: 36029795
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and Safety of Nirmatrelvir/Ritonavir in Severe Hospitalized Patients with COVID-19 and in Patients at High Risk for Progression to Critical Illness: A Real-World Study.
    Chen X; Zhu Y; Shen L; Zhou D; Feng N; Tong Q
    J Intensive Care Med; 2024 Aug; 39(8):742-750. PubMed ID: 38356292
    [No Abstract]   [Full Text] [Related]  

  • 17. Real-world effectiveness of molnupiravir and nirmatrelvir plus ritonavir against mortality, hospitalisation, and in-hospital outcomes among community-dwelling, ambulatory patients with confirmed SARS-CoV-2 infection during the omicron wave in Hong Kong: an observational study.
    Wong CKH; Au ICH; Lau KTK; Lau EHY; Cowling BJ; Leung GM
    Lancet; 2022 Oct; 400(10359):1213-1222. PubMed ID: 36216007
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effectiveness of azvudine against severe outcomes among hospitalized COVID-19 patients in Xinjiang, China: a single-center, retrospective, matched cohort study.
    Kapar A; Xie S; Guo Z; Nan Y; Du Y; Yin X; Gong T; Gu X; Zhou Y; Lu W; Yang A; Luo Z; Dai J; Wang K; Zhao S; Wang K
    Expert Rev Anti Infect Ther; 2024 Jul; 22(7):569-577. PubMed ID: 38822541
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of Azvudine and Nirmatrelvir/Ritonavir and Combined Use in Patients with COVID-19.
    Hu CY; Cui WS; Lei Y; Tang YW; Zhang YY; Su QM; Peng F; Zeng YF; Song JL; Luo CN; Zhou Y; Li XY; Zhao ZX
    Infect Drug Resist; 2023; 16():7797-7808. PubMed ID: 38148771
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy of Nirmatrelvir-Ritonavir versus Azvudine for COVID-19 Treatment in Tibet: A Retrospective Study.
    Zhao X; Cheng Y; Zhang M; Qianda B; Zhouma B; Yangzhen B; Zheng Y; Zhang S; Zhao H
    Infect Drug Resist; 2023; 16():6053-6060. PubMed ID: 37719651
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.